HighTide Therapeutics (HKG:2511) appointed Filip Surmont as chief medical officer to lead its global medical strategy, clinical development, and medical affairs, according to a Monday Hong Kong bourse filing.
Surmont has more than 30 years of healthcare and pharmaceutical experience, including leadership roles at Wyeth, Pfizer, and AstraZeneca, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.